Syndax Pharmaceuticals Inc. ( (SNDX) ) has released its Q1 earnings. Here is a breakdown of the information Syndax Pharmaceuticals Inc. presented to its investors.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company, is focused on advancing innovative cancer therapies, with key products including the FDA-approved Revuforj and Niktimvo. The company recently reported its financial results for the first quarter of 2025, highlighting significant achievements in product launches and clinical trials.
In the first quarter of 2025, Syndax Pharmaceuticals reported a combined net revenue of $34 million from its two main products, Revuforj and Niktimvo. Revuforj, an oral menin inhibitor, achieved $20 million in net revenue during its first full quarter post-launch, while Niktimvo, co-commercialized with Incyte, generated $13.6 million in its first partial quarter. The company also submitted a supplemental New Drug Application for Revuforj and initiated a pivotal trial for its combination therapy in acute leukemia.
Key financial metrics indicate that Syndax ended the quarter with $602.1 million in cash, cash equivalents, and investments, and reported a net loss of $84.8 million. The company’s research and development expenses increased due to ongoing trials and milestone payments, while selling, general, and administrative expenses rose due to increased sales and marketing efforts.
Looking ahead, Syndax Pharmaceuticals remains focused on advancing its clinical pipeline and achieving profitability. The management is optimistic about the potential of its innovative therapies to unlock multi-billion-dollar opportunities, supported by a solid financial position and strategic collaborations.